Suggested remit: To appraise the clinical and cost effectiveness of osimertinib within its marketing authorisation for adjuvant treatment of non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 3835

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
12 October 2020 - 09 November 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
01 September 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance